SCHEMBL8263187

SCHEMBL8263187

CCOC(=O)c1ccc(Cl)c(-c2ccc(NC(=O)c3c(F)cccc3F)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IL2 P60568 3/20 0.64
MAPT P10636 4/20 0.57
TP53 P04637 3/20 0.57
RAB9A P51151 3/20 0.51
CYP1A2 P05177 1/20 0.51
CETP P11597 2/20 0.49
TRPV1 Q8NER1 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
GAA P10253 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
RORC P51449 1/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4762631 0.90 IL2 (0.61) IL2MAPTTP53RAB9ASMN1; SMN2
SCHEMBL4724528 0.83 IL2 (0.69) IL2MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL16363192 0.82 IL2 (0.71) IL2MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3209227 0.82 RAB9A (0.65) MAPTTP53RAB9ACYP1A2CETP
SCHEMBL1825939 0.81 IL2 (0.76) IL2MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL1641679 0.80 RAB9A (0.65) MAPTRAB9ACYP1A2SMN1; SMN2NPC1
SCHEMBL5550916 0.79 STIM1 (0.56) IL2MAPTTP53RAB9ACYP1A2
SCHEMBL4769885 0.79 IL2 (0.65) IL2RAB9ANPC1MEN1KMT2A
SCHEMBL3208835 0.79 RAB9A (0.65) MAPTRAB9ACYP1A2SMN1; SMN2NPC1
SCHEMBL2812601 0.79 NPC1 (0.49) IL2MAPTRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846372-B1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP (US) 2014-04-16 EP disclosed
US-20140039009-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-02-06 US disclosed
US-8202999-B2 biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders SYNTA PHARMACEUTICALS CORP. (US) 2012-06-19 US disclosed
US-8202999-B2 biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders SYNTA PHARMACEUTICALS CORP. (US) 2012-06-19 US disclosed
WO-2006083477-A2 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140039009-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR8, CXCR2 IL2 72/4885MAPT 2475/4885TP53 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.